Robert Molinari

Robert Molinari

Company: Retrotope

Job title: Former Co-founding Chief Executive Officer


Dr. Molinari was the co-founding CEO (from 2008 until 8/2020) of Retrotope, a company focused on novel drugs against diseases of degeneration and aging, with Dr. Charles Cantor, a member of the US Academy of Sciences, and Dr. Mikhail Shchepinov.  Retrotope is advancing an entirely new class of very safe, lipid-based drugs against orphan and major market neurodegenerative and retinal diseases.  It currently has two late stage pivotal trials underway in orphan neuromuscular disease, and has preclinical and clinical proof of concept in a wide range of mitochondrial and neurodegenerative diseases, including Parkinson’s, Alzheimer’s, Friedreich’s ataxia, Progressive SupraNuclear Palsy, and ALS.

Prior to Retrotope, Dr. Molinari has been a successful founding CEO in companies developing research tools for drug discovery.  Dr. Molinari received his Bachelor’s degree in Chemistry, magna cum laude, from Dartmouth College, a Ph.D., in physical chemistry from Brown University, and an MBA at the Amos Tuck School of Business at Dartmouth.

Dr. Molinari spent his early career at Raychem Corporation and McKinsey and Company where he specialized in technology management, and completed extensive work for early biotechnology research companies. In 1988, Dr. Molinari left McKinsey to become the founding CEO of a company which improved the productivity of DNA sequencing. In 1993, Dr. Molinari started a custom DNA synthesis company, Protogene Laboratories, from technology out of the Stanford Medical School. Protogene quickly became the largest manufacturer of custom DNA reagents in the world, and was acquired by Life Technologies, Inc. Dr. Molinari then led companies that developed extensive technology in chemical synthesis of custom DNA chip assays, gene assembly from oligonucleotides, and high throughput chemical and gene synthesis.

Dr. Molinari has published perspectives on technology transformations in healthcare and the Future of pharmaceuticals as part of the Institute for the Future’s HealthCare Horizons program.


Preclinical & Early Clinical Evidence of Stabilized Polyunsaturated Fatty Acid (PUFA) as Drug Therapy in Diseases of Mitochondrial Deficiency 2:45 pm

• Examine how a worsening cascade of lipid peroxidation of PUFAs leads to cell dysfunction and death – often through mitochondrial loss of function • View how reducing lipid peroxidation with the use of stabilized lipid drugs mitigates LPO-based cell death may halt or reverse progression of disease by restoring mitochondrial function • Showcase how…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.